What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to provide financial information from Pfizer's previous Form 10-Q filing (for the quarter ended April 2, 2006) in a new XBRL (eXtensible Business Reporting Language) format, as part of the SEC's voluntary pilot program to test this technology.

Are the financial statements in this filing the official audited financial statements for Pfizer?

No, the financial information provided in the XBRL format within this filing is unaudited. Pfizer explicitly states that investors should continue to rely on the officially filed versions of its financial statements and not make investment decisions based solely on this XBRL data.

What specific financial statements are included in the XBRL exhibit?

The XBRL exhibit includes: (i) Condensed Consolidated Statements of Income for the three months ended April 2, 2006, and April 3, 2005; (ii) Condensed Consolidated Balance Sheets as of April 2, 2006, and December 31, 2005; and (iii) Condensed Consolidated Statements of Cash Flows for the three months ended April 2, 2006, and April 3, 2005.

Does this filing impose any new legal liability on Pfizer regarding the XBRL data?

No, according to Rule 402 of Regulation S-T, the information furnished in this 8-K, including the XBRL exhibit, is not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. Therefore, it is not subject to the liabilities of that section, and it will not be automatically incorporated into other registration statements unless specifically referenced.

PFE 8-K SEC Disclosure — Nov 30, 2006

Summary

This Form 8-K filing from Pfizer Inc. (PFE), dated November 30, 2006, primarily serves to furnish XBRL-formatted financial data from its previously filed Quarterly Report on Form 10-Q for the period ending April 2, 2006. This includes condensed consolidated statements of income, balance sheets, and cash flows for relevant comparative periods. The company is participating in the SEC's voluntary XBRL pilot program to test this new digital reporting format. Investors should note that the XBRL data provided in this filing is unaudited and is not considered the official financial statement filing. Pfizer advises its investors to continue to rely on the officially filed versions of its financial reports and not to make investment decisions based solely on the information presented in this XBRL exhibit. The purpose is purely for technological testing and exploration of the XBRL format.

Key Highlights

1Pfizer is furnishing XBRL-formatted financial data as part of the SEC's voluntary XBRL pilot program.
2The XBRL data includes condensed consolidated statements of income, balance sheets, and cash flows.
3The furnished XBRL data pertains to Pfizer's Quarterly Report on Form 10-Q for the quarter ended April 2, 2006.
4The XBRL financial information is explicitly stated as unaudited.
5Investors are cautioned that this XBRL data is not the official financial filing and should not be the sole basis for investment decisions.
6The company advises reliance on the officially filed versions of its financial reports.
7This filing does not create new liabilities under Section 18 of the Exchange Act for the XBRL information.

PFIZER INC 8-K Report, Corporate Update (Nov 30, 2006)

Summary

Key Highlights

Frequently Asked Questions